Viela Bio downgraded by HC Wainwright & Co. with a new price target
$VIE
Major Pharmaceuticals
Health Care
HC Wainwright & Co. downgraded Viela Bio from Buy to Neutral and set a new price target of $53.00 from $52.00 previously
Save time and jump to the most important pieces.
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra
Guggenheim downgraded Viela Bio from Buy to Neutral
Wedbush downgraded Viela Bio from Outperform to Neutral
Wedbush downgraded Viela Bio from Outperform to Neutral and set a new price target of $43.00
4 - Viela Bio, Inc. (0001734517) (Issuer)
4 - Viela Bio, Inc. (0001734517) (Issuer)
4 - Viela Bio, Inc. (0001734517) (Issuer)
SC 13D/A - Viela Bio, Inc. (0001734517) (Subject)
SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)
SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)
15-12B - Viela Bio, Inc. (0001734517) (Filer)
S-8 POS - Viela Bio, Inc. (0001734517) (Filer)
S-8 POS - Viela Bio, Inc. (0001734517) (Filer)
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial results and provided program and business highlights for the fourth quarter and full year ended December 31, 2020. “2020 was a year of great progress for Viela, despite the many external challenges resulting from the COVID-19 global pandemic,” said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. “Most significantly, we received FDA approval for UPLIZNA® to treat adult patients with AQP4+ NMOSD and achieve
-No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy- GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neur
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra